Clinical Trial

A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible Urticaria

Study acronym: CHILL-MC
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a first-in-human study aimed at determining the safety of a single dose of GTX-B001 in healthy participants and in people with chronic inducible urticaria.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-12; most recent amendment 2026-01-28.
Status change: Not Yet Recruiting → Recruiting 2025-11-27
Trial Details
NCT Number NCT07181369
Lead Sponsor Granular Therapeutics Limited
Conditions Healthy Subjects, Cold Urticaria, Symptomatic Dermographism, Chronic Inducible Urticaria
Enrollment 72 participants
Start Date 2025-10-06
Primary Completion 2027-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-01-30